als
Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly
May 7, 2025Mergers and Acquisitions Alchemab Therapeutics, Corporate, Eli Lilly and Company, Immunology, M&A, als, immunology, neurodegenerative conditions
Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, its …
Neurizon makes appointments to executive team
April 24, 2025Recruitment, Senior Management Neurizon, Neurology, als, biotech, neurodegenerative diseases
Neurizon Therapeutics, a clinical-stage biotech company focusing on treatments for neurodegenerative diseases, has announced three leadership appointments. These will support …
NeuroSense shares update from ALS treatment trial
July 2, 2024Research and Development NeuroSense, Neurology, als, clinical trial
NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study which assessed PrimeC …
NeuroSense partners with PhaseV on upcoming phase 3 ALS trial
May 16, 2024Research and Development NeuroSense, Neurology, als, clinical trials
NeuroSense has announced that it has partnered with PhaseV for its upcoming phase 3 trial of PrimeC as a treatment …
New treatment could extend survival in amyotrophic lateral sclerosis patients
October 20, 2020Manufacturing and Production, Research and Development als, pharma
Research into an experimental drug combination shows that it could potentially extend the lives for sufferers of amyotrophic lateral sclerosis …
Astellas and Cytokinetics’ reldesemtiv falls short at Phase 2 in ALS
May 7, 2019Manufacturing and Production, Sales and Marketing Astellas, als, amyotrophic lateral sclerosis, cytokinetics, pharma
Cytokinetics has announced at the American Academy of Neurology (AAN) that its fast skeletal muscle troponin activator (FSTA) reldesemtiv fell …
Aquinnah Pharmaceuticals receives $3.4 million grant to advance ALS therapies
June 21, 2018Research and Development, Sales and Marketing Aquinnah Pharmaceuticals, als, amyotrophic lateral sclerosis, pharma
Aquinnah Pharmaceuticals has announced that it has been awarded a $3.4 million grant from the National Institute of Neurological Disorders …
AB Science will not seek review of masitinib rejection in Europe
May 29, 2018Manufacturing and Production, Sales and Marketing EMA, Europe, ab science, als, masitinib, pharma
AB Science has U-turned on its pursuit of a do-over on its marketing application of masitinib in Europe after the …
CHMP rejects AB Science’s ALS therapy in Europe
April 23, 2018Sales and Marketing AB Sciences, EMA, European Medicines Agency, ab science, als, masitinib, pharma
AB Science has revealed that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a …
FDA approves first ALS/Lou Gehrig’s disease therapy in 22 years
May 18, 2017Research and Development, Sales and Marketing Mitsubishi Tanabe Pharma, als
The FDA has announced that it has approved Mitsubishi Tanabe Pharma’s Radicava (edaravone) for the treatment of amyotrophic lateral sclerosis(ALS), …
New therapy wins EMA orphan drug designation for ALS
August 9, 2016Manufacturing and Production, Research and Development EMA, Ice Bucket Challenge, ab science, als, masitinib, oprhan drug designation
French pharma company AB Science has announced that the European Medicines Agency has granted orphan drug status to masitinib for …
Eisai seeks new ALS drug approval
May 28, 2015Sales and Marketing Eisai, Japan, als, mecobalamin
Eisai is hoping that existing neurology drug mecobalamin can be a new option for the difficult-to-treat condition amyotrophic lateral sclerosis …
Biogen Idec hires from Novartis to head ALS
September 1, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen IDEC, Novartis, als, donald johns
Biogen Idec has appointed Dr Donald Johns as the vice president of its amyotrophic lateral sclerosis (ALS) innovation hub unit. …
Lilly signs Lou Gehrig’s disease deal
November 21, 2013Research and Development, Sales and Marketing als, hill, lilly, lou gehrig
Eli Lilly & Company has signed a deal with US charity Project A.L.S. to find new treatments for the debilitating …
Latest content
FibroFind appoints Lee Borthwick as CEO
